Recruiting 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors NCT07189871 Conditions Adnexal Diseases, Breast Diseases, Breast Neoplasms, +60 more Locations Dothan Hematology & Oncology — Dothan, Alabama, United States BAMF Health — Grand Rapids, Michigan, United States Nebraska Cancer Specialists — Omaha, Nebraska, United States XCancer — Omaha, Nebraska, United States View Trial Details
Not Yet Recruiting A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1) NCT07488923 Conditions Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +20 more Locations Hackensack University Medical Center — Hackensack, New Jersey, United States NYU Langone Health — New York, United States Sarah Cannon Research Institute (SCRI) — Nashville, Tennessee, United States UT Southwestern Medical Center — Dallas, Texas, United States View more locations Show fewer locations Loading locations... View Trial Details
